---
title: Mandatory notification of trade
description: Mandatory notification of trade - Gentian Diagnostics ASA 15.12.2022
---

<https://www.gentian.com/investor-relations-stock-information/investors-news>

# [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1671105790989)

 Written by [Kristin Hart](https://www.gentian.com/investor-relations-stock-information/investors-news/author/kristin-hart) | Dec 15, 2022 12:04:02 PM

Moss, 15 December 2022

Reference is made to the annual general meeting 18 May 2022 where a statement of remuneration to key personnel was given. In accordance with this statement the board of Gentian Diagnostics ASA has allocated a total of 219,996 options to key employees under the existing option program.

The following number of options have been allocated to primary insiders of Gentian Diagnostics ASA:

Hilja Ibert, Chief Executive Officer: 80,000 options. Following the allocations Ms. Ibert holds 6,525 shares and 359,924 options

Njaal Kind, Group Chief Financial Officer: 19,996 options. Following the allocations Mr. Kind holds 21,125 shares and 175,666 options in the Company.

Torsten Knüttel, Vice President R&D: 10,000 options. Following the allocation Mr. Knüttel holds 1,125 shares and 40,000 options in the Company.

Jack Andreassen, Vice President Business Development: 10,000 options. Following the allocation Mr. Andreassen hold 4,385 shares and 32,500 options in the Company.

Markus Jaquemar, Vice President Sales and Marketing: 25,000 options. Following the allocation Mr. Jaquemar holds 47,500 options in the Company.

The exercise price for the options granted is NOK 46,67 being the average volume-weighted share price on the Oslo Stock Exchange from 1 January 2022 to 13 December 2022. The right to exercise the options is vested over a period of 2 years, with 50% of the options vesting by the end of each year as follows: (i) 50% of the options granted, no earlier than 3 years after the allocation date (ii) 50% of the options granted, no earlier than 4 years after the allocation date.

Attached are the [notifications of the transactions](https://www.gentian.com/hubfs/IR%20documents/2022%20Notification%20forms%20options.pdf) pursuant to the market abuse regulation article 19.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

For further information, please contact:

 

Njaal Kind  
CFO, Gentian Diagnostics  
E-mail: [njaal.kind@gentian.no](mailto:njaal.kind@gentian.no)  
Cell Phone. +47 919 06 525

To see the announcement follow this link: [https://newsweb.oslobors.no/message/578263](https://newsweb.oslobors.no/message/578263)

[View full post](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1671105790989)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Kristin Hart"
  },
  "dateModified" : "2022-12-15T12:04:02.214Z",
  "datePublished" : "2022-12-15T12:04:02Z",
  "headline" : "Mandatory notification of trade",
  "image" : {
    "@type" : "ImageObject",
    "height" : 60,
    "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
    "width" : 60
  },
  "mainEntityOfPage" : "https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1671105790989",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Investor News"
  }
}
```